- Home
- VCIG vs LPCN Comparison
VCIG vs LPCN Comparison
Compare VCIG & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCIG
- LPCN
- Stock Information
- Founded
- VCIG 2013
- LPCN 1997
- Country
- VCIG Malaysia
- LPCN United States
- Employees
- VCIG N/A
- LPCN N/A
- Industry
- VCIG Diversified Commercial Services
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- VCIG Consumer Discretionary
- LPCN Health Care
- Exchange
- VCIG Nasdaq
- LPCN Nasdaq
- Market Cap
- VCIG 15.4M
- LPCN 36.8M
- IPO Year
- VCIG 2023
- LPCN N/A
- Fundamental
- Price
- VCIG $0.10
- LPCN $5.46
- Analyst Decision
- VCIG
- LPCN Strong Buy
- Analyst Count
- VCIG 0
- LPCN 1
- Target Price
- VCIG N/A
- LPCN $10.00
- AVG Volume (30 Days)
- VCIG 8.6M
- LPCN 23.4K
- Earning Date
- VCIG 11-10-2024
- LPCN 11-06-2024
- Dividend Yield
- VCIG 10.14%
- LPCN N/A
- EPS Growth
- VCIG N/A
- LPCN N/A
- EPS
- VCIG 0.16
- LPCN N/A
- Revenue
- VCIG $23,548,256.00
- LPCN $4,800,930.00
- Revenue This Year
- VCIG N/A
- LPCN N/A
- Revenue Next Year
- VCIG N/A
- LPCN N/A
- P/E Ratio
- VCIG $0.60
- LPCN N/A
- Revenue Growth
- VCIG 89.38
- LPCN 8630.55
- 52 Week Low
- VCIG $0.08
- LPCN $2.31
- 52 Week High
- VCIG $3.71
- LPCN $11.79
- Technical
- Relative Strength Index (RSI)
- VCIG 38.34
- LPCN 61.75
- Support Level
- VCIG $0.08
- LPCN $4.89
- Resistance Level
- VCIG $0.11
- LPCN $5.85
- Average True Range (ATR)
- VCIG 0.02
- LPCN 0.38
- MACD
- VCIG -0.00
- LPCN 0.04
- Stochastic Oscillator
- VCIG 31.85
- LPCN 64.83
About VCIG VCI Global Limited
VCI Global Ltd is a holding company. The principal activities of the Company and its subsidiaries are the provision of business Strategy consultancy and technology development solution consultancy. The firm organized its consulting services into three main segments: Business Strategy Consultancy; Technology Consultancy; and Others. It derives the majority of its revenue from the Business Strategy Consultancy segment which focuses on listing solutions, investor relations, and boardroom strategies consultancy. It has established a diverse local and international clientele, providing them with its services in both local and cross-border listings. Its role begins with pre-listing diagnosis and planning to the finalization of the entire listing process.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.